Please assess the completion status of the following clinical trial:

Trial Title: CAE Plus LAI in Individuals With Bipolar Disorder at Risk for Treatment Non-adherence (BD-CAEL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Individuals age 18 and older with BD Type 1 or 2 as confirmed by the Mini International Psychiatric Inventory (MINI).~2. Known to have medication treatment adherence problems as identified by the Treatment Routines Questionnaire (TRQ, 20% or more missed medications in past week or past month)~3. Screening the Brief Psychiatric Rating Scale (BPRS) score of ≥ 36~4. Ability to be rated on psychiatric rating scales.~5. Willingness to take long-acting injectable antipsychotic medication (LAI)~6. Currently in treatment or scheduled to receive treatment at a Community Mental Health Clinic (CMHC) or other clinical setting able to provide mental health care during and after study participation~7. Able to provide written, informed consent to study participation.~Exclusion Criteria:~1. Individuals on LAI immediately prior to study enrollment.~2. Individuals with known intolerance or resistance to either oral aripiprazole or LAI formulation of aripiprazole~3. Prior or current treatment with clozapine~4. Medical condition or illness, which in the opinion of the research psychiatrist, would interfere with the patient's ability to participate in the trial~5. Physical dependence on substances (alcohol or illicit drugs) likely to lead to withdrawal reaction during the course of the study in the clinical opinion of the treated research psychiatrist~6. Immediate risk of harm to self or others~7. Female who is currently pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patient Noncompliance (Type: EXPERIMENTAL): Subjects enrolled in the study will receive both Abilify Miantena and the Customized Adherence Enhancement (CAE) intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).